Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Don't be surprised to see its shares fall even lower this year.

4 Numbers That Make Ocugen an Extremely Risky Buy

Ocugen was once one of the hottest stocks on the market. After soaring from 18 cents to $17.6 back to about $2.5.

The Biggest Reasons to Avoid Ocugen for Now

The Street's bullishness on this biotech is hardly justified.

Wall Street Thinks This Stock Could Soar by 242%; Here's Why It's Not a Buy

The agency has declined to issue authorization for Ocugen's pediatric COVID-19 vaccine.

Is Ocugen Stock Heading for $0 After the FDA's Recent Decision?

MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be presenting at the 34th Annual Roth Conference.

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

The company has hit several roadblocks along the coronavirus vaccine path.

Is There Any Hope for Ocugen?

The company needs some good news to turn things around.

Ocugen Fell Today: Is It a Buy Now?

Last week's sell-off is continuing into this week.

Why Ocugen Stock Is Falling Today

Ocugen has tried repeatedly to bring drugs to market, first as Histogenics and later under its current name. The post Ocugen Is Two Strikes in With a Third in the Books appeared first on InvestorPlace.

Ocugen Is Two Strikes in With a Third in the Books

The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.

Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA

The U.S. FDA refused to grant Emergency Use Authorization for COVID-19 vaccine Covaxin in immunizing kids.

Why Ocugen Stock Is Crashing Today

Ocugen (OCGN) stock is falling hard on Friday after the FDA rejected its Emergency Use Authorization request for Covaxin. The post Ocugen Latest News: What OCGN Stock Investors Need to Know About the FDA's Covaxin Rejection appeared first on InvestorPlace.

Ocugen Latest News: What OCGN Stock Investors Need to Know About the FDA's Covaxin Rejection

The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age. Ocugen Inc (NASDAQ: OCGN) is working with the vaccine's developer, Bharat Biotech of India, to bring Covaxin to the U.S..

FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin

Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age. Ocugen says the company intends to continue working.

Why Ocugen Shares Are Falling

MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age. Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN™.

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q4 2021 Results - Earnings Call Transcript

The company's shares jumped on positive news from the FDA.

Is Ocugen Stock a Buy Now?

Shares of Ocugen Inc. OCGN, -2.40% gained 4.7% in premarket trading on Friday after the company said the Food and Drug Administration lifted the clinical hold for the COVID-19 vaccine it's developing with Bharat Biotech, a privately held biotech based in Hyderabad. The vaccine candidate is currently in a Phase 2/3 clinical trial, and Ocugen said it expects to start "this immuno-bridging and broadening clinical trial as soon as possible.

Ocugen's stock jumps 4% after saying FDA lifted hold on trial for experimental COVID-19 shot

Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

Plug Power

Root

Select analysts and investment banks are looking for these fast-growing stocks to skyrocket in 2022.

3 Growth Stocks With Monster Upside of 253% to 650%, According to Wall Street

Ocugen is down more than 20% after announcing a common stock offering. Could this possibly present a buying opportunity for OCGN stock?

Is OCGN Stock a Buy After 20% Plunge? One Analyst Thinks It Can Go to $15.

AMC Entertainment

Clover Health Investments

Peloton

QuantumScape

SoFi Technologies

Zillow

These stocks to sell run the gamut in terms of industry, but they all have one thing in common: the pros think they ought to be sold. The post 7 Popular Stocks That Pros Agree You Should Punt From Your Portfolio appeared first on InvestorPlace.

7 Popular Stocks That Pros Agree You Should Punt From Your Portfolio

After rising sharply in recent days, Ocugen shares are again falling on news that the company is issuing $50 million of common stock. The post OCGN Stock Alert: The $50 Million Reason Ocugen Is Tanking Today appeared first on InvestorPlace.

OCGN Stock Alert: The $50 Million Reason Ocugen Is Tanking Today

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the pricing of its underwritten public offering of approximately 15,973,420 million shares of its common stock for gross proceeds of approximately $53.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about February 25, 2022, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to approximately 2,396,013 million additional shares of its common stock.

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

Ocugen's path to entry in the North American market is highly uncertain, making OCGN stock a remarkably risky bet at this point. The post Ocugen Is Too Uncertain as Time Runs Out for Covaxin's Approval appeared first on InvestorPlace.

News for Ocugen, Inc. Stock (OCGN)